CLB تصريحات هيئة الأوراق المالية والبورصات - Core Laboratories Inc.- التقرير السنوي، بيان التوكيل، نشرة الإصدار

الإحصائيات الأساسية

LEI	724500MDYY5VBSAF5W50
CIK	1000229

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Core Laboratories Inc.

SEC Filings (Chronological Order)

توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.

June 12, 2023	SC 13G/A	CLB / Core Laboratories Inc / ALGER ASSOCIATES INC - CORE LABORATORIES NV Passive Investment Core Laboratories NV UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 12, 2023	15F-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 15F-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14273 Core Laboratories N.V. (Exact name of registrant as specif
May 2, 2023	S-8 POS	As filed with the Securities and Exchange Commission on May 1, 2023 S-8 POS As filed with the Securities and Exchange Commission on May 1, 2023 Registration No.
May 2, 2023	S-8 POS	As filed with the Securities and Exchange Commission on May 1, 2023 S-8 POS As filed with the Securities and Exchange Commission on May 1, 2023 Registration No.
May 2, 2023	S-8 POS	As filed with the Securities and Exchange Commission on May 1, 2023 S-8 POS As filed with the Securities and Exchange Commission on May 1, 2023 Registration No.
May 2, 2023	S-8 POS	As filed with the Securities and Exchange Commission on May 1, 2023 S-8 POS As filed with the Securities and Exchange Commission on May 1, 2023 Registration No.
May 2, 2023	S-8 POS	As filed with the Securities and Exchange Commission on May 1, 2023 S-8 POS As filed with the Securities and Exchange Commission on May 1, 2023 Registration No.
May 2, 2023	S-8 POS	As filed with the Securities and Exchange Commission on May 1, 2023 S-8 POS As filed with the Securities and Exchange Commission on May 1, 2023 Registration No.
May 2, 2023	S-8 POS	As filed with the Securities and Exchange Commission on May 1, 2023 S-8 POS As filed with the Securities and Exchange Commission on May 1, 2023 Registration No.
May 2, 2023	S-8 POS	As filed with the Securities and Exchange Commission on May 1, 2023 S-8 POS As filed with the Securities and Exchange Commission on May 1, 2023 Registration No.
May 2, 2023	S-8 POS	As filed with the Securities and Exchange Commission on May 1, 2023 S-8 POS As filed with the Securities and Exchange Commission on May 1, 2023 Registration No.
May 2, 2023	S-8 POS	As filed with the Securities and Exchange Commission on May 1, 2023 S-8 POS 1 d477271ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on May 1, 2023 Registration No. 33-98588 Registration No. 33-98590 Registration No. 33-80473 Registration No. 333-40639 Registration No. 333-40641 Registration No. 333-43859 Registration No. 333-73772 Registration No. 333-73774 Registration No. 333-231277 Registration No. 333-248137 UNITED STATES SECURITIES AN
May 2, 2023	EX-99.25	EX-99.25 NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on May 15, 2023, pursuant to the provisions of Rule 12d2-2 (a).
April 28, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 28, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Definitive Proxy State
April 27, 2023	10-Q	Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14273 CORE LABO
April 26, 2023	EX-99	CORE LABORATORIES N.V. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS FIRST QUARTER 2023 RESULTS: • REVENUE OF $128 MILLION; UP SLIGHTLY SEQUENTIALLY; UP 11% YEAR-OVER-YEAR • OPERATING INCOME OF $6.5 MILLION; EX-ITEMS OF $14.5 MILLION, FLAT SEQUENTIALLY; UP OVER 100% YEAR-OVER-YEAR • OPERATING MARGINS, EX-ITEMS, OF 11%, WITH YEAR-OVER-YEAR INCREMENTAL MARGINS EXCEEDING 55% • GAAP EPS OF $0.05; EX-ITEMS, $0.19; UP O
April 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 CORE LABORATORIES UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation) (C
April 4, 2023	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation) (Co
February 28, 2023	DEFM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 14, 2023	SC 13G/A	CLB / Core Laboratories N.V. / ALGER ASSOCIATES INC - CORE LABORATORIES NV Passive Investment SC 13G/A 1 d408856dsc13ga.htm CORE LABORATORIES NV UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Core Laboratories N.V. (Name of Issuer) Common Shares (Title of Class of Securities) N22717107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropria
February 10, 2023	EX-4.1	Description of Share Capital Exhibit 4.1 2. DESCRIPTION OF SHARE CAPITAL The following summary of the terms of our ordinary shares does not purport to be complete and is subject to and qualified in its entirety by reference to applicable Dutch law and our articles of association, which we refer to as our Articles of Association. Our Articles of Association and relevant Dutch law, not this summary, define your rights as a hold
February 10, 2023	EX-21.1	Significant Subsidiaries of the Registrant Exhibit 21.1 Significant Subsidiaries of the Registrant at December 31, 2022 Name Legal Seat Ownership % Core Laboratories Australia PTY LTD Perth, Australia 100% Core Laboratories Canada Ltd. Alberta, Canada 100% Core Laboratories International B.V. Amsterdam, The Netherlands 100% Core Laboratories LP Delaware, United States 100% Core Laboratories Malaysia SDN BHD Kuala Lumpur, Malaysia 100% Core
February 10, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14273 CORE LABORATORI
February 9, 2023	SC 13G/A	CLB / Core Laboratories N.V. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0659-corelaboratoriesnv.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Core Laboratories NV Title of Class of Securities: Common Stock CUSIP Number: N22717107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to desi
February 3, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2023 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation)
February 3, 2023	EX-99.1	Core Laboratories LP [CLB] Q4 2022 Earnings Conference Call Thursday, February 2, 2023, 8:30am ET. Exhibit 99.1 Core Laboratories LP [CLB] Q4 2022 Earnings Conference Call Thursday, February 2, 2023, 8:30am ET. Company Participants: Gwen Gresham, Senior Vice President and Head of Investor Relations Larry Bruno, Chairman and Chief Executive Officer Chris Hill, Chief Financial Officer Analysts: Samantha Hoh, Evercore ISI Simon Galligani, Awilco AS Presentation Operator: Good morning, and welcome
February 1, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2023 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation)
February 1, 2023	EX-99.1	CORE LABORATORIES N.V. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS FOURTH QUARTER AND FULL YEAR 2022 RESULTS FROM CONTINUING OPERATIONS: • FOURTH QUARTER REVENUE OF $128 MILLION; UP SLIGHTLY SEQUENTIALLY • FOURTH QUARTER OPERATING INCOME OF $16 MILLION; EX-ITEMS OF $15 MILLION, UP 10% SEQUENTIALLY • FOURTH QUARTER OPERATING MARGIN, EX-ITEMS, OF 12% WITH SEQUENTIAL INCREMENTAL MARGINS EXCEEDING 80%, DRIVEN BY PRO
January 17, 2023	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2023 CORE LABORATORIE 425 1 d431525d425.htm 425 Filed by Core Laboratories Luxembourg S.A. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Core Laboratories N.V. Commission File No.: 001-14273 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 1
January 17, 2023	EX-99.1	CORE LAB ANNOUNCES PROPOSED REDOMESTICATION TO THE UNITED STATES EX-99.1 2 d431525dex991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB ANNOUNCES PROPOSED REDOMESTICATION TO THE UNITED STATES AMSTERDAM (17 January 2023)—Core Laboratories N.V. (NYSE: “CLB US”) (“Core”, “Core Lab”, or the “Company”) announces the Company’s Board of Directors has approved a plan to reorganize the Company’s corporate structure, which will include redomestication of the par
January 17, 2023	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2023 CORE LABORATORIE 425 1 d431525d425.htm 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2023 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Juris
January 17, 2023	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2023 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation)
November 4, 2022	EX-99.1	CORE LAB ANNOUNCES VOLUNTARY DELISTING FROM EURONEXT AMSTERDAM Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB ANNOUNCES VOLUNTARY DELISTING FROM EURONEXT AMSTERDAM AMSTERDAM (4 November 2022) ? Core Laboratories N.V. (NYSE: "CLB US" and Euronext Amsterdam: "CLB NA") (?Core Lab? or the ?Company?) announced today its decision to proceed with the voluntary delisting of its shares from Euronext Amsterdam. The Company has been dual listed on the New York Stock Exchan
November 4, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2022 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation)
October 28, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14273 CORE
October 26, 2022	EX-99.1	CORE LABORATORIES N.V. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (amounts in thousands, except per share data) Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS THIRD QUARTER 2022 RESULTS FROM CONTINUING OPERATIONS: ? THIRD QUARTER REVENUE OF $126 MILLION; UP 4% SEQUENTIALLY; UP 7% YEAR-OVER-YEAR ? THIRD QUARTER OPERATING INCOME UP OVER 25% SEQUENTIALLY AND, EX-ITEMS, UP OVER 38% SEQUENTIALLY ? THIRD QUARTER SEQUENTIAL INCREMENTAL MARGINS, EX-ITEMS, EXCEED 55%, DRIVEN BY RESERVOIR DESCRIPTION ? THIRD QUA
October 26, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2022 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation)
July 28, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14273 CORE LABOR
July 27, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2022 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation) (Co
July 27, 2022	EX-99.1	CORE LABORATORIES N.V. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (amounts in thousands, except per share data) Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS SECOND QUARTER 2022 RESULTS FROM CONTINUING OPERATIONS: ? SECOND QUARTER REVENUE OF $120.9 MILLION; UP 5% SEQUENTIALLY; UP 2% YEAR-OVER-YEAR ? SECOND QUARTER SEQUENTIAL INCREMENTAL MARGINS, EX-ITEMS, 43%, DRIVEN BY RESERVOIR DESCRIPTION ? SECOND QUARTER GAAP EPS OF $0.15; EPS, EX-ITEMS, $0.12 ? RENEWS AND EXTENDS REVOLVING CREDIT FACILITY THROUGH
July 27, 2022	EX-10.1	Eighth Amended and Restated Credit Agreement, dated as of June 25, 2022, among Core Laboratories N.V., and Core Laboratories (U.S.) Interests Holdings, Inc., and the lenders party thereto and Bank of America, N.A., as administrative agent Exhibit 10.1 CUSIPS: 21867HAE0 21867HAF7 EIGHTH AMENDED AND RESTATED CREDIT AGREEMENT Dated as of JULY 25, 2022 CORE LABORATORIES N.V., and CORE LABORATORIES (U.S.) Interests Holdings, Inc., as Borrowers, BANK OF AMERICA, N.A., as Administrative Agent, collateral agent, Swing Line Lender and L/C Issuer, WELLS FARGO BANK, N.A., as SYNDICATION agent, COMERICA BANK, as documentation agent, and The Ot
July 27, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2022 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation) (Co
June 29, 2022	11-K	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) X ANNUAL REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR TRANSITION REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 (NO FEE REQUIRED) For the transition period from to Commission File Number 001-14273 A. Full t
June 9, 2022	EX-99.1	CORE LAB ANNOUNCES $60,000,000 “AT-THE-MARKET” EQUITY OFFERING PROGRAM Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB ANNOUNCES $60,000,000 ?AT-THE-MARKET? EQUITY OFFERING PROGRAM AMSTERDAM (9 June 2022) ? Core Laboratories N.V. (NYSE and Euronext Amsterdam: ?CLB?) (?Core,? ?Core Lab? or the ?Company?) announced today that it has established an ?at-the-market? equity offering program (the ?ATM Program?) under which it may, from time to time, sell its common shares havin
June 9, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation) (Com
June 9, 2022	424B5	Common Shares Having an Aggregate Offering Price of Up to Core Laboratories N.V. Table of Contents Filed Pursuant to Rule 424(b)(5) SEC File No. 333-245691 PROSPECTUS SUPPLEMENT (To Prospectus dated August 13, 2020) Common Shares Having an Aggregate Offering Price of Up to $60,000,000 Core Laboratories N.V. This prospectus supplement relates to the issuance and sale of our common shares from time to time through Wells Fargo Securities, LLC and BofA Securities, Inc. (each, a ?s
June 9, 2022	EX-1.1	Equity Distribution Agreement, dated June 9, 2022, by and between Core Laboratories N.V. and Wells Fargo Securities, LLC. Exhibit 1.1 CORE LABORATORIES N.V. Up to $60,000,000 of Common Shares EQUITY DISTRIBUTION AGREEMENT Dated: June 9, 2022 TABLE OF CONTENTS Page SECTION 1. Description of Securities 1 SECTION 2. Placements 2 SECTION 3. Sale of Placement Securities by the Designated Agent 4 SECTION 4. Suspension of Sales 4 SECTION 5. Representations and Warranties 5 SECTION 6. Sale and Delivery to the Designated Agen
June 9, 2022	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) Core Laboratories N.V. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Exhibit 107 Calculation of Filing Fee Tables ????.. 424(b)(5) (Form Type) ????????????????????.. Core Laboratories N.V. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee R
June 8, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation) (Com
June 7, 2022	CORRESP	2 June 7, 2022 Karl Hiller Branch Chief Office of Energy & Transportation Division of Corporate Finance United States Securities and Exchange Commission 100 F.
June 2, 2022	CORRESP	Twelve-Months December 31, 2021 June 2, 2022 Karl Hiller Branch Chief Office of Energy & Transportation Division of Corporate Finance United States Securities and Exchange Commission 100 F.
May 24, 2022	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) SD 1 clb-conflictminerals.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) Van Heuven Go
May 19, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation) (Com
April 28, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14273 CORE LABO
April 27, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2022 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation) (C
April 27, 2022	EX-99.1	CORE LABORATORIES N.V. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (amounts in thousands, except per share data) Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS FIRST QUARTER 2022 RESULTS FROM CONTINUING OPERATIONS: ? FIRST QUARTER REVENUE OF $115.3 MILLION; UP 6% YEAR-OVER-YEAR ? FIRST QUARTER GAAP EPS OF $(0.04); EPS, EX-ITEMS, $0.08 ? LAUNCH OF INDUSTRY CARBON CAPTURE AND SEQUESTRATION ("CCS") CONSORTIUM ? CCS STRATEGIC ALLIANCE WITH TALOS ENERGY INC. ? REDUCES NET DEBT BY $3.3 MILLION ? ANNOUNCES Q2
March 24, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
March 22, 2022	DEF 14A	Schedule 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
March 16, 2022	EX-99.1	1 Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB ANNOUNCES: ? REVISED Q1 2022 GUIDANCE ? CONSTRUCTIVE VIEW ON 2022 COMPANY OUTLOOK ? LAUNCH OF INDUSTRY CARBON CAPTURE AND SEQUESTRATION CONSORTIUM ? FIRST QUARTER 2022 EARNINGS WEBCAST AT 7:30 A.M. CDT / 2:30 P.M. CEST ON 28 APRIL 2022 AMSTERDAM (16 March 2022) - Core Laboratories N.V. (NYSE: "CLB US" and Euronext Amsterdam: "CLB NA") (?Core?, ?Core Lab?
March 16, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2022 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation) (C
March 11, 2022	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
February 10, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14273 CORE LABORATORI
February 10, 2022	EX-4.1	Description of Share Capital 2. DESCRIPTION OF SHARE CAPITAL The following summary of the terms of our ordinary shares does not purport to be complete and is subject to and qualified in its entirety by reference to applicable Dutch law and our articles of association, which we refer to as our Articles of Association. Our Articles of Association and relevant Dutch law, not this summary, define your rights as a holder of our or
February 10, 2022	EX-21.1	Significant Subsidiaries of the Registrant Exhibit 21.1 Significant Subsidiaries of the Registrant at December 31, 2021 Name Legal Seat Ownership % Core Laboratories Australia PTY LTD Perth, Australia 100% Core Laboratories Canada Ltd. Alberta, Canada 100% Core Laboratories International B.V. Amsterdam, The Netherlands 100% Core Laboratories LP Delaware, United States 100% Core Laboratories Malaysia SDN BHD Kuala Lumpur, Malaysia 100% Core
February 9, 2022	SC 13G/A	CLB / Core Laboratories N.V. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Core Laboratories NV Title of Class of Securities: Common Stock CUSIP Number: N22717107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
February 2, 2022	EX-99.1	CORE LABORATORIES N.V. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (amounts in thousands, except per share data) Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS FOURTH QUARTER AND FULL YEAR 2021 RESULTS FROM CONTINUING OPERATIONS: ? FOURTH QUARTER REVENUE OF $125.1 MILLION; UP 6% SEQUENTIALLY; UP 10% YEAR-OVER-YEAR ? FOURTH QUARTER PRODUCTION ENHANCEMENT REVENUE UP 15% SEQUENTIALLY; UP 51% YEAR-OVER-YEAR ? FOURTH QUARTER INTERNATIONAL REVENUE UP 14% YEAR-OVER-YEAR ? FOURTH QUARTER GAAP EPS OF $0.06; EPS,
February 2, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2022 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation)
January 10, 2022	SC 13G/A	CLB / Core Laboratories N.V. / ALGER ASSOCIATES INC - CORE LABORATORIES NV Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Core Laboratories N.V. (Name of Issuer) Common Shares (Title of Class of Securities) N22717107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
January 4, 2022	SC 13G/A	CLB / Core Laboratories N.V. / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* CORE LABORATORIES N.V. (Name of Issuer) Common Stock (Title of Class of Securities) N22717107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
October 29, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14273 CORE
October 27, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2021 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation)
October 27, 2021	EX-99.1	CORE LABORATORIES N.V. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (amounts in thousands, except per share data) Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS THIRD QUARTER 2021 RESULTS FROM CONTINUING OPERATIONS: ? REVENUE OF $118.0 MILLION ? GAAP EPS OF $0.02; $0.18, EX-ITEMS ? FREE CASH FLOW IMPROVES SEQUENTIALLY TO $8.8 MILLION ? REDUCED NET DEBT BY $5.4 MILLION ? ANNOUNCES Q4 2021 QUARTERLY DIVIDEND AMSTERDAM (27 October 2021) - Core Laboratories N.V. (NYSE: "CLB US" and Euronext Amsterdam: "CLB N
October 19, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2021 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation)
October 19, 2021	EX-10.2	Amendment and Restated Employment Agreement, by and between Core Laboratories N.V. and Christopher S. Hill, dated October 18, 2021 (1) Exhibit 10.2 Employment Agreement (Amended and Restated as of October 15, 2021) THIS EMPLOYMENT AGREEMENT (this ?Agreement?) is made by and between CORE LABORATORIES N.V. and Christopher S. Hill (?Executive?). W I T N E S S E T H: WHEREAS, Executive is currently an employee of Core Laboratories N.V. and/or one or more of its Affiliates (?Company?); and WHEREAS, Company desires to continue to emplo
October 19, 2021	EX-10.3	Amendment and Restated Employment Agreement, by and between Core Laboratories N.V. and Gwendolyn Y. Schreffler, dated October 18, 2021 (1) Exhibit 10.3 Employment Agreement (Amended and Restated as of October 15, 2021) THIS EMPLOYMENT AGREEMENT (this ?Agreement?) is made by and between CORE LABORATORIES N.V. and Gwendolyn Y. Schreffler (?Executive?). W I T N E S S E T H: WHEREAS, Executive is currently an employee of Core Laboratories N.V. and/or one or more of its Affiliates (?Company?); and WHEREAS, Company desires to continue to e
October 19, 2021	EX-10.4	Employment Agreement, by and between Core Laboratories N.V. and Mark D. Tattoli, dated October 18, 2021 (1) Exhibit 10.4 Employment Agreement THIS EMPLOYMENT AGREEMENT (this ?Agreement?) is made by and between CORE LABORATORIES N.V. and Mark D. Tattoli (?Executive?). W I T N E S S E T H: WHEREAS, Executive is currently an employee of Core Laboratories N.V. and/or one or more of its Affiliates (?Company?); and WHEREAS, Company desires to continue to employ Executive on the terms and conditions, and for t
October 19, 2021	EX-10.1	Amendment and Restated Employment Agreement, by and between Core Laboratories N.V. and Lawrence V. Bruno, dated October 18, 2021 (1) Exhibit 10.1 Employment Agreement (Amended and Restated as of October 15, 2021) THIS EMPLOYMENT AGREEMENT (this ?Agreement?) is made by and between CORE LABORATORIES N.V. and Lawrence V. Bruno (?Executive?). W I T N E S S E T H: WHEREAS, Executive is currently an employee of Core Laboratories N.V. and/or one or more of its Affiliates (?Company?); and WHEREAS, Company desires to continue to employ
July 30, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14273 CORE LABOR
July 28, 2021	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2021 CORE LABORATORIES N UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2021 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation) (Co
July 28, 2021	EX-99.1	CORE LABORATORIES N.V. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (amounts in thousands, except per share data) Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS SECOND QUARTER 2021 RESULTS FROM CONTINUING OPERATIONS: ? REVENUE OF $118.7 MILLION; UP 10% SEQUENTIALLY; UP 3% YEAR-OVER-YEAR ? GAAP EPS OF $0.17; $0.18, EX-ITEMS; UP 19% SEQUENTIALLY; UP 31% YEAR-OVER-YEAR ? PRODUCTION ENHANCEMENT REVENUE UP 27% SEQUENTIALLY ? REDUCED NET DEBT BY $5.8 MILLION ? ANNOUNCING Q3 2021 QUARTERLY DIVIDEND AMSTERDAM (2
June 29, 2021	11-K	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) X ANNUAL REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR TRANSITION REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 (NO FEE REQUIRED) For the transition period from to Commission File Number 001-14273 A. Full t
June 10, 2021	SC 13G/A	CLB / Core Laboratories N.V. / ALGER ASSOCIATES INC - CORE LABORATORIES N.V. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Core Laboratories N.V. (Name of Issuer) Common Shares (Title of Class of Securities) N22717107 (CUSIP Number) May 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche
May 28, 2021	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) Van Heuven Goedhartlaan 7 B 1181 LE Amstelveen
May 19, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2021 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation) (Com
April 23, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14273 CORE LABO
April 21, 2021	EX-99.1	Quarter Ending 2020 2021 Jun. 30 Sept. 30 Dec. 31 Mar. 31 Jun. 30 Sept. 30 Dec. 31 Maximum Leverage Ratio 3.00 2.75 2.50 2.00 1.50 1.00 Core Lab’s leverage ratio of 2.21 at 30 June 2020 Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS FIRST QUARTER 2021 RESULTS FROM CONTINUING OPERATIONS: ? COMPANY FIRST QUARTER REVENUE OF $108.4 MILLION; DOWN 4.7% SEQUENTIALLY ? FIRST QUARTER GAAP EPS OF $0.18; $0.15, EX-ITEMS; DOWN 15.6% SEQUENTIALLY ? COMPANY COMPLETES PREVIOUSLY ANNOUNCED AT-THE-MARKET PROGRAM ? CORE REDUCES NET DEBT BY $65.0 MILLION ? CORE GENERATES FCF OF $5.2 MILLION ?
April 21, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2021 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation) (C
March 19, 2021	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
March 19, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
March 5, 2021	PRE 14A	- PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
February 16, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Core Laboratories NV (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) December Core Laboratories NV UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 11, 2021	SC 13G/A	SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* CORE LABORATORIES N.V. (Name of Issuer) Common Stock (Title of Class of Securities) N22717107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
February 10, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Core Laboratories NV Title of Class of Securities: Common Stock CUSIP Number: N22717107 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
February 10, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* Core Laboratories N.V. (Name of Issuer) COMMON SHARES (Title of Class of Securities) (CUSIP Number) Decem UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* Core Laboratories N.V. (Name of Issuer) COMMON SHARES (Title of Class of Securities) N22717107 (CUSIP Number) December 31, 2020 - Year End Filing (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu
February 8, 2021	EX-21.1	Significant Subsidiaries of the Registrant Exhibit 21.1 Significant Subsidiaries of the Registrant at December 31, 2020 Name Legal Seat Ownership % Core Laboratories Australia PTY LTD Perth, Australia 100% Core Laboratories Canada Ltd. Alberta, Canada 100% Core Laboratories International B.V. Amsterdam, The Netherlands 100% Core Laboratories LP Delaware, United States 100% Core Laboratories Malaysia SDN BHD Kuala Lumpur, Malaysia 100% Core
February 8, 2021	EX-10.14	Employment Agreement between Core Laboratories N.V. and Gwendolyn Y. Schreffler, Dated March 1, 2019 Exhibit 10.14 Employment Agreement Dated March 1, 2019 THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made by and between CORE LABORATORIES N.V. and Gwendolyn Y. Schreffler (“Executive”). W I T N E S S E T H: WHEREAS, Executive is currently an employee of Core Laboratories N.V. and/or one or more of its Affiliates (“Company”); and WHEREAS, Company desires to continue to employ Executive on the te
February 8, 2021	EX-4.1	Description of Share Capital Exhibit 4.1 DESCRIPTION OF SHARE CAPITAL The following summary of the terms of our ordinary shares does not purport to be complete and is subject to and qualified in its entirety by reference to applicable Dutch law and our articles of association, which we refer to as our Articles of Association. Our Articles of Association and relevant Dutch law, not this summary, define your rights as a holder
February 8, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14273 CORE LABORATORI
January 27, 2021	EX-99.1	Quarter ended December 31, 2020 (in $ millions) Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS FOURTH QUARTER AND FULL YEAR 2020 RESULTS FROM CONTINUING OPERATIONS: • COMPANY FOURTH QUARTER REVENUE OF $114 MILLION; UP 8% SEQUENTIALLY • FOURTH QUARTER GAAP EPS OF $0.31; $0.18, EX-ITEMS; UP OVER 10% SEQUENTIALLY • CORE GENERATES FCF FOR 19TH CONSECUTIVE YEAR; $46 MILLION FOR 2020 • CORE REDUCES NET DEBT BY $49 MILLION OR 16.5% FOR 2020 • RES
January 27, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2021 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation)
January 15, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2021 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation)
January 15, 2021	EX-99.1	CORE LAB ANNOUNCES Q1 2021 QUARTERLY DIVIDEND Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB ANNOUNCES Q1 2021 QUARTERLY DIVIDEND AMSTERDAM (15 January 2021) - The Board of Supervisory Directors of Core Laboratories N.V. (NYSE: "CLB US" and Euronext Amsterdam Exchange: "CLB NA") has announced a cash dividend of $0.01 per share of common stock payable in the first quarter of 2021. This first quarter dividend would mean a total payout of $0.04 per
December 17, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2020 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation)
December 17, 2020	EX-99.1	CORE LAB ANNOUNCES $60,000,000 AT-THE-MARKET EQUITY OFFERING PROGRAM EX-99.1 Exhibit 99.1 CORE LAB ANNOUNCES $60,000,000 AT-THE-MARKET EQUITY OFFERING PROGRAM AMSTERDAM, the Netherlands December 17, 2020 — Core Laboratories N.V. (NYSE: “CLB US” and Euronext Amsterdam: “CLB NA”) (“Core,” “Core Lab,” or the “Company”) announced today that it has established an at-the-market equity offering program (the “ATM Program”) under which it may, from time to time, sell its co
December 17, 2020	EX-1.1	Equity Distribution Agreement, dated December 17, 2020, by and between Core Laboratories N.V. and Wells Fargo Securities, LLC. EX-1.1 Exhibit 1.1 EXECUTION VERSION CORE LABORATORIES N.V. Up to $60,000,000 of Common Shares EQUITY DISTRIBUTION AGREEMENT Dated: December 17, 2020 TABLE OF CONTENTS Page SECTION 1. Description of Securities 1 SECTION 2. Placements 2 SECTION 3. Sale of Placement Securities by Wells Fargo Securities 3 SECTION 4. Suspension of Sales 4 SECTION 5. Representations and Warranties 4 SECTION 6. Sale and
December 17, 2020	424B5	CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Proposed maximum aggregate offering price Amount of registration fee Common Shares (EUR 0.02 par value per share) $60,000,000.00(1) $6,546(1) 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) SEC File No. 333-245691 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Proposed maximum aggregate offering price Amount of registration fee Common Shares (EUR 0.02 par value per share) $60,000,000.00(1) $6,546(1) (1) Computed pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the Securit
October 22, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14273 CORE
October 21, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2020 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation)
October 21, 2020	EX-99.1	Face Value ($ Millions) Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS THIRD QUARTER 2020 RESULTS FROM CONTINUING OPERATIONS: • COMPANY REVENUE OF $105.4 MILLION; DOWN 9% SEQUENTIALLY • GAAP EPS OF $0.07; $0.16, EX-ITEMS • CORE GENERATES FCF FOR 76TH CONSECUTIVE QUARTER OF $18.5 MILLION • CORE REDUCES NET DEBT BY $16.2 MILLION • CORE ANNOUNCES $60 MILLION OF 5-YEAR & 7-YEAR PRIVATE PLACEMENT NOTES AMSTERDAM (21 Octo
October 16, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - 8-K NOTE PURCHASE AGREEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2020 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation)
October 16, 2020	EX-99.1	CORE LAB ANNOUNCES PRIVATE PLACEMENT OF $60 MILLION IN SENIOR NOTES Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB ANNOUNCES PRIVATE PLACEMENT OF $60 MILLION IN SENIOR NOTES AMSTERDAM (16 October 2020) - Core Laboratories N.V. (NYSE: "CLB US" and Euronext Amsterdam: "CLB NA") ("Core", "Core Lab", or the "Company") announced the Company, through its subsidiary, Core Laboratories (U.S.) Interests Holdings, Inc. (the “Issuer”), completed a private placement of $60 milli
October 16, 2020	EX-10.1	Note Purchase Agreement, dated as of October 16, 2020. Exhibit 10.1 Execution Version Core Laboratories (U.S.) Interests Holdings, Inc., as Issuer Core Laboratories N.V., as Parent Guarantor $45,000,000 4.09% Senior Notes Series A due January 12, 2026 $15,000,000 4.38% Senior Notes Series B due January 12, 2028 Note Purchase Agreement Dated October 16, 2020 4319729 Table of Contents SectionHeadingPage Section 1. Authorization of Notes1 Section 2. Sale
October 15, 2020	EX-99.1	CORE LAB ANNOUNCES Q4 2020 QUARTERLY DIVIDEND Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB ANNOUNCES Q4 2020 QUARTERLY DIVIDEND AMSTERDAM (15 October 2020) - The Board of Supervisory Directors of Core Laboratories N.V. (NYSE: "CLB US" and Euronext Amsterdam Exchange: "CLB NA") has announced a cash dividend of $0.01 per share of common stock payable in the fourth quarter of 2020. This fourth quarter dividend amount, when added to the Q1 2020 di
October 15, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2020 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation)
August 19, 2020	S-8	- S-8 S-8 As filed with the Securities and Exchange Commission on August 19, 2020 Registration No.
August 13, 2020	S-3ASR	- S-3ASR S-3ASR Table of Contents As filed with the Securities and Exchange Commission on August 13, 2020 Registration No.
July 24, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14273 CORE LABOR
July 22, 2020	EX-99.1	Forecast 2020 Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS SECOND QUARTER 2020 RESULTS FROM CONTINUING OPERATIONS: • COMPANY REVENUE OF $116 MILLION • GAAP EPS OF $(0.13); $0.14, EX-ITEMS • CORE GENERATES FCF FOR 75TH CONSECUTIVE QUARTER OF $24 MILLION • CORE REDUCES NET DEBT BY $23 MILLION • CORE AMENDS CREDIT FACILITY AMSTERDAM (22 July 2020) - Core Laboratories N.V. (NYSE: "CLB US" and Euronext Amster
July 22, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2020 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation) (Co
July 17, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2020 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation) (Co
July 17, 2020	EX-99.1	CORE LAB ANNOUNCES Q3 2020 QUARTERLY DIVIDEND Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB ANNOUNCES Q3 2020 QUARTERLY DIVIDEND AMSTERDAM (17 July 2020) - The Board of Supervisory Directors of Core Laboratories N.V. (NYSE: "CLB US" and Euronext Amsterdam Exchange: "CLB NA") ("Core", "Core Lab", or the "Company") has announced a cash dividend of $0.01 per share of common stock payable in the third quarter of 2020. This third quarter dividend am
July 8, 2020	SC 13G/A	AMS:CLB / Core Laboratories NV / VAN ECK ASSOCIATES CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.2)* Core Laboratories N.V. (Name of Issuer) COMMON SHARES (Title of Class of Securities) N22717107 (CUSIP Number) June 19, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche
June 26, 2020	11-K	- 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) X ANNUAL REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR TRANSITION REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 (NO FEE REQUIRED) For the transition period from to Commission File Number 001-14273 A. Full t
June 23, 2020	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2020 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation) (Co
June 23, 2020	EX-99.1	Forecast 2020 Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB ANNOUNCES: • AMENDMENT TO REVOLVING CREDIT FACILITY • FURTHER EXPANSION OF COST REDUCTION INITIATIVES • SECOND QUARTER 2020 EARNINGS WEBCAST AT 7:30 A.M. CDT / 2:30 P.M. CEST ON 23 JULY 2020 AMSTERDAM (23 June 2020) - Core Laboratories N.V. (NYSE: "CLB US" and Euronext Amsterdam: "CLB NA") ("Core", "Core Lab", or the "Company") announced today that the C
June 23, 2020	EX-10.1	Amendment No. 1 to Credit Agreement, by and among Core Laboratories N.V., Core Laboratories (U.S.) Interests Holding, Inc., and the lenders party thereto and Bank of America, N.A., as administrative agent, dated June 22, 2020 Exhibit 10.1 #6184110 AMENDMENT NO. 1 TO CREDIT AGREEMENT This Amendment No. 1 to Seventh Amended and Restated Credit Agreement (this “Amendment”), dated as of June 22, 2020 (the “Effective Date”), is entered into among CORE LABORATORIES N.V., a Netherlands limited liability company, (the “Parent”), CORE LABORATORIES (U.S.) INTERESTS HOLDINGS, INC., a Texas corporation (the “US Borrower” and, toge
May 21, 2020	SD	- SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands 001-14273 Not Applicable (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) Strawinskyl
May 20, 2020	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2020 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation) (Com
May 12, 2020	DEFA14A	May 12, 2020 DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
May 8, 2020	SC 13G/A	AMS:CLB / CORE LABORATORIES N.V. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Core Laboratories NV Title of Class of Securities: Common Stock CUSIP Number: N22717107 Date of Event Which Requires Filing of this Statement: April 30, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ R
April 28, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2020 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation) (C
April 28, 2020	EX-99.1	CORE LAB ANNOUNCES Q2 2020 QUARTERLY DIVIDEND Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB ANNOUNCES Q2 2020 QUARTERLY DIVIDEND AMSTERDAM (28 April 2020) - The Board of Supervisory Directors of Core Laboratories N.V. (NYSE: "CLB US" and Euronext Amsterdam Exchange: "CLB NA") has announced a cash dividend of $0.01 per share of common stock payable in the second quarter of 2020. This second quarter dividend amount, if maintained for the remainin
April 24, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14273 CORE LABO
April 22, 2020	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2020 CORE LABORATORIES UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2020 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation) (C
April 22, 2020	EX-99.1	Forecast 2020 Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS FIRST QUARTER 2020 RESULTS FROM CONTINUING OPERATIONS: • COMPANY REVENUE OF $152.4 MILLION • GAAP EPS OF $(2.44); $0.31, EX-ITEMS • CORE GENERATES FCF FOR 74TH CONSECUTIVE QUARTER OF $19 MILLION • CORE REDUCES NET DEBT • COMPANY MAINTAINS OILFIELD SERVICE-LEADING ROIC OF 12.3% • RECORDS GOODWILL IMPAIRMENTS OF $122 MILLION FOR PRODUCTION ENHANCEM
April 1, 2020	SC 13G/A	AMS:CLB / CORE LABORATORIES N.V. / VAN ECK ASSOCIATES CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* Core Laboratories N.V. (Name of Issuer) COMMON SHARES (Title of Class of Securities) N22717107 (CUSIP Number) March 20, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch
March 27, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2020 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation) (C
March 27, 2020	DEFA14A	March 27, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
March 27, 2020	EX-99.1	CORE LAB RESCHEDULES TIME AND LOCATION OF ITS 2020 ANNUAL SHAREHOLDER MEETING WHILE MAINTAINING MEETING DATE OF MAY 20, 2020 Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB RESCHEDULES TIME AND LOCATION OF ITS 2020 ANNUAL SHAREHOLDER MEETING WHILE MAINTAINING MEETING DATE OF MAY 20, 2020 AMSTERDAM (27 March 2020) – Core Laboratories N.V. (NYSE: "CLB US" and Euronext Amsterdam: "CLB NA"), (the “Company” or “Core Lab”) announces that on March 20, 2020, it filed its definitive proxy on form DEF-14A with the U.S. Securities and
March 20, 2020	DEFA14A	March 20, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
March 20, 2020	DEF 14A	Core Laboratories N.V. 2020 Long-Term Incentive Plan (1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin
March 16, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2020 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation) (C
March 16, 2020	EX-99.1	### Exhibit 99.1 FOR IMMEDIATE RELEASE AMSTERDAM (16 March 2020) - Core Laboratories N.V. (NYSE: "CLB US" and Euronext Amsterdam: "CLB NA") (“Core”, “Core Lab”, or the “Company”) is announcing immediate actions in response to current market volatility, operational disruption related to COVID-19, and the oil and gas industry outlook. In addition, Core Lab is making further corporate and operating cost
March 6, 2020	PRE 14A	CLB / Core Laboratories N.V. PRE 14A - - PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☑ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
March 5, 2020	EX-10.1	Amendment to Employment Agreement, by and between Core Laboratories N.V. and Lawrence V. Bruno, dated March 1, 2020. Exhibit 10.1 AMENDMENT TO EMPLOYMENT AGREEMENT (Dated March 1, 2020) WHEREAS, Core Laboratories N.V. and Lawrence V. Bruno have heretofore entered into that certain Employment Agreement (Dated March 1, 2019) (the “Agreement”); and WHEREAS, the parties desire to amend the Agreement as provided herein; NOW, THEREFORE, the Agreement is amended hereby effective as of January 1, 2020 (the “Effective Da
March 5, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2020 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation) (Co
February 14, 2020	SC 13G/A	CLB / Core Laboratories N.V. / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* CORE LABORATORIES N.V. (Name of Issuer) Common Stock (Title of Class of Securities) N22717107 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
February 14, 2020	SC 13G/A	CLB / Core Laboratories N.V. / Clearbridge Investments, LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 15)* CORE LABORATORIES N V (Name of Issuer) Common Stock (Title of Class of Securities) N22717107 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t
February 13, 2020	SC 13G	CLB / Core Laboratories N.V. / VAN ECK ASSOCIATES CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Core Laboratories N.V. (Name of Issuer) COMMON SHARES (Title of Class of Securities) N22717107 (CUSIP Number) December 31, 2019 - Year End Filing (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
February 12, 2020	SC 13G/A	CLB / Core Laboratories N.V. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Core Laboratories NV Title of Class of Securities: Common Stock CUSIP Number: N22717107 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
February 10, 2020	EX-21.1	Significant Subsidiaries of the Registrant Exhibit 21.1 Significant Subsidiaries of the Registrant at December 31, 2019 Name Legal Seat Ownership % Core Laboratories Australia PTY LTD Perth, Australia 100% Core Laboratories Canada Ltd. Alberta, Canada 100% Core Laboratories International B.V. Amsterdam, The Netherlands 100% Core Laboratories LP Delaware, United States 100% Core Laboratories Malaysia SDN BHD Kuala Lumpur, Malaysia 100% Core
February 10, 2020	EX-4.1	Description of Share Capital Exhibit 4.1 DESCRIPTION OF SHARE CAPITAL The following summary of the terms of our ordinary shares does not purport to be complete and is subject to and qualified in its entirety by reference to applicable Dutch law and our articles of association, which we refer to as our Articles of Association. Our Articles of Association and relevant Dutch law, not this summary, define your rights as a holder
February 10, 2020	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14273 CORE LABORATORI
February 5, 2020	SC 13G/A	CLB / Core Laboratories N.V. / WCM INVESTMENT MANAGEMENT/CA - FORM SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* CORE LABORATORIES NV (Name of Issuer) Common (Title of Class of Securities) N22717107 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule
January 29, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2020 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation)
January 29, 2020	EX-99.1	CORE LABORATORIES N.V. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (amounts in thousands, except per share data) Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS FOURTH QUARTER 2019 RESULTS FROM CONTINUING OPERATIONS: • COMPANY REVENUE OF $157 MILLION • GAAP EPS OF $0.23; $0.38, EX-ITEMS • RESERVOIR DESCRIPTION OPERATING MARGINS 17%, EX-ITEMS, UP FROM 16% YEAR-OVER-YEAR • CORE GENERATES FCF FOR 73RD CONSECUTIVE QUARTER • COMPANY POSTS OILFIELD SERVICE-LEADING ROIC OF 20.2% • CORE NOTIFIED OF INCLUSION IN
January 14, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2020 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation)
January 14, 2020	EX-99.1	CORE LAB ANNOUNCES Q1 2020 QUARTERLY DIVIDEND Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB ANNOUNCES Q1 2020 QUARTERLY DIVIDEND AMSTERDAM (14 January 2020) - The Board of Supervisory Directors of Core Laboratories N.V. (NYSE: "CLB US" and Euronext Amsterdam Exchange: "CLB NA") has announced a cash dividend of $0.25 per share of common stock payable in the first quarter of 2020. This first quarter dividend would mean a total payout of $1.00 per
December 30, 2019	EX-99.1	### Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB ANNOUNCES: • UPDATED FOURTH QUARTER 2019 GUIDANCE • INITIAL FIRST QUARTER 2020 GUIDANCE • FUTURE QUARTERLY DIVIDENDS REDUCED TO $0.25 PER SHARE AMSTERDAM (30 December 2019) - Core Laboratories N.V. (NYSE: "CLB US" and Euronext Amsterdam: "CLB NA") (“Core”, “Core Lab”, or the “Company”) is announcing revised guidance from continuing operations for the fou
December 30, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2019 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation)
November 12, 2019	SC 13G/A	CLB / Core Laboratories N.V. / Clearbridge Investments, LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 14)* CORE LABORATORIES N V (Name of Issuer) Common Stock (Title of Class of Securities) N22717107 (CUSIP Number) October 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to
October 25, 2019	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14273 CORE
October 23, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2019 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation)
October 23, 2019	EX-99.1	CORE LABORATORIES N.V. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (amounts in thousands, except per share data) Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS THIRD QUARTER 2019 RESULTS FROM CONTINUING OPERATIONS: • COMPANY REVENUE OF $173 MILLION, UP 2.5% SEQUENTIALLY • GAAP EPS OF $0.54; $0.50, EX-ITEMS, UP 9% SEQUENTIALLY • CORE GENERATES FCF FOR 72ND CONSECUTIVE QUARTER • RESERVOIR DESCRIPTION REVENUE HIGHEST SINCE Q4 2015 • RESERVOIR DESCRIPTION OPERATING MARGINS OF 18%, EX-ITEMS, UP 290 BPS YEAR-
October 8, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2019 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation) (
October 8, 2019	EX-99.1	CORE LAB ANNOUNCES Q4 2019 QUARTERLY DIVIDEND FOR IMMEDIATE RELEASE CORE LAB ANNOUNCES Q4 2019 QUARTERLY DIVIDEND AMSTERDAM (8 October 2019) - The Board of Supervisory Directors of Core Laboratories N.
August 12, 2019	SC 13G/A	CLB / Core Laboratories N.V. / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* CORE LABORATORIES N.V. (Name of Issuer) Common Stock (Title of Class of Securities) N22717107 (CUSIP Number) July 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch
July 26, 2019	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14273 CORE LABOR
July 24, 2019	EX-99.1	CORE LABORATORIES N.V. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (amounts in thousands, except per share data) Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS SECOND QUARTER 2019 RESULTS FROM CONTINUING OPERATIONS: • GAAP EPS OF $0.43; $0.46, EX-ITEMS • RESERVOIR DESCRIPTION INTERNATIONAL REVENUE UP 8% YEAR-OVER-YEAR • RESERVOIR DESCRIPTION OPERATING MARGINS OF 15%, EX-ITEMS, OF 17%, UP 360 BPS SEQUENTIALLY AND UP 270 BPS YEAR-OVER-YEAR • RESERVOIR DESCRIPTION SEQUENTIAL AND YEAR-OVER-YEAR INCREMENTAL
July 24, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2019 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation) (Co
July 12, 2019	EX-99.1	CORE LAB ANNOUNCES Q3 2019 QUARTERLY DIVIDEND FOR IMMEDIATE RELEASE CORE LAB ANNOUNCES Q3 2019 QUARTERLY DIVIDEND AMSTERDAM (12 July 2019) - The Board of Supervisory Directors of Core Laboratories N.
July 12, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): July 12, 2019 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands Not Applicable (State or other jurisdict
June 24, 2019	11-K	CLB / Core Laboratories N.V. 11-K - - 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) X ANNUAL REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR TRANSITION REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 (NO FEE REQUIRED) For the transition period from to Commission File Number 001-14273 A. Full t
May 29, 2019	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): May 23, 2019 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands Not Applicable (State or other jurisdicti
May 28, 2019	SD	CLB / Core Laboratories N.V. SD - - 2018 CONFLICT MINERALS REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands 001-14273 Not Applicable (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) Strawinskyl
May 8, 2019	S-8	Form S-8 Registration Statement pursuant to 2014 Long-Term Incentive Plan S-8 As filed with the Securities and Exchange Commission on May 8, 2019 Registration No.
April 26, 2019	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14273 CORE LABO
April 24, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2019 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-14273 Not Applicable (State or Other Jurisdiction of Incorporation) (C
April 24, 2019	EX-99.1	CORE LABORATORIES N.V. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (amounts in thousands, except per share data) Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS FIRST QUARTER 2019 RESULTS FROM CONTINUING OPERATIONS: • REVENUE OF $169.2 MILLION • GAAP EPS OF $0.90; $0.44, EX-ITEMS • PRODUCTION ENHANCEMENT OPERATING MARGINS, EX-ITEMS, OF 19%, UP 160 BPS SEQUENTIALLY • COMPANY POSTS OILFIELD SERVICE-LEADING ROIC • FCF REACHES 102% OF INCOME FROM CONTINUING OPERATIONS, EX-ITEMS; GENERATES POSITIVE FCF FOR 70
April 16, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): April 16, 2019 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands Not Applicable (State or other jurisdic
April 16, 2019	EX-99.1	CORE LAB ANNOUNCES Q2 2019 QUARTERLY DIVIDEND FOR IMMEDIATE RELEASE CORE LAB ANNOUNCES Q2 2019 QUARTERLY DIVIDEND AMSTERDAM (16 April 2019) - The Board of Supervisory Directors of Core Laboratories N.
March 20, 2019	DEFA14A	CLB / Core Laboratories N.V. DEFA14A PROXY FOR 2019 ANNUAL MEETING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
March 20, 2019	DEF 14A	CLB / Core Laboratories N.V. DEF 14A - 2019 PROXY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Defin
March 8, 2019	PRE 14A	CLB / Core Laboratories N.V. PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: þ Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
March 6, 2019	EX-10.1	Employment Agreement between Core Laboratories N.V. and Lawrence V. Bruno, dated March 1, 2019 (1) EX-10.1 Exhibit 10.1 Employment Agreement Dated March 1, 2019 THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made by and between CORE LABORATORIES N.V. and Lawrence V. Bruno (“Executive”). W I T N E S S E T H: WHEREAS, Executive is currently an employee of Core Laboratories N.V. and/or one or more of its Affiliates (“Company”); and WHEREAS, Company desires to continue to employ Executive on the t
March 6, 2019	EX-10.2	Employment Agreement between Core Laboratories N.V. and Christopher S. Hill, dated March 1, 2019 (1) EX-10.2 Exhibit 10.2 Employment Agreement Dated March 1, 2019 THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made by and between CORE LABORATORIES N.V. and Christopher S. Hill (“Executive”). W I T N E S S E T H: WHEREAS, Executive is currently an employee of Core Laboratories N.V. and/or one or more of its Affiliates (“Company”); and WHEREAS, Company desires to continue to employ Executive on the
March 6, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2019 CORE LABORATORIES N.
February 14, 2019	SC 13G/A	CLB / Core Laboratories N.V. / Clearbridge Investments, LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 13)* CORE LABORATORIES N V (Name of Issuer) Common Stock (Title of Class of Securities) N22717107 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t
February 14, 2019	SC 13G/A	CLB / Core Laboratories N.V. / WCM INVESTMENT MANAGEMENT/CA - FORM SC 13G/A Passive Investment WCM Investment Management - Schedule 13G/A - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* CORE LABORATORIES NV (Name of Issuer) Common (Title of Class of Securities) N22717107 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check th
February 13, 2019	SC 13G	CLB / Core Laboratories N.V. / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CORE LABORATORIES N.V. (Name of Issuer) Common Stock (Title of Class of Securities) N22717107 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S
February 11, 2019	EX-10.16	Amendment to Restated Employment Agreement between Core Laboratories N.V. and David M. Demshur effective January 1, 2015 AMENDMENT TO EMPLOYMENT AGREEMENT (Restated as of December 31, 2007) WHEREAS, Core Laboratories N.
February 11, 2019	SC 13G/A	CLB / Core Laboratories N.V. / VANGUARD GROUP INC Passive Investment corelaboratoriesnv.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6 )* Name of issuer: Core Laboratories NV Title of Class of Securities: Common Stock CUSIP Number: N22717107 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the appropriate
February 11, 2019	EX-10.11	Form of Core Laboratories 2017 Performance Share Award Program Agreement (ROIC Based) CORE LABORATORIES N.V. 2014 LONG-TERM INCENTIVE PLAN (As Amended and Restated Effective as of May 13, 2014) Performance Share Award Restricted Share Agreement (ROIC Based) THIS AGREEMENT is made as of between Core Laboratories N.V., a Dutch limited liability company (the “Company”), and (“Participant”) in order to carry out the purposes of the Core Laboratories N.V. 2014 Long-Term Incentive Plan a
February 11, 2019	10-K	CLB / Core Laboratories N.V. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) Q ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14273 CORE LABORATORI
January 30, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): January 30, 2019 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands Not Applicable (State or other jurisd
January 30, 2019	EX-99.1	CORE LABORATORIES N.V. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (amounts in thousands, except per share data) Three Months Ended % Variance Dec 31, 2018 Sep 30, 2018 Dec 31, 2017 vs Q3-18 vs Q4-17 REVENUE $ 173,207 $ 182,146 $ 170,1 FOR IMMEDIATE RELEASE CORE LAB REPORTS FOURTH QUARTER 2018 RESULTS FROM CONTINUING OPERATIONS: • REVENUE OF $173.
January 15, 2019	EX-99.1	CORE LAB ANNOUNCES Q1 2019 QUARTERLY DIVIDEND FOR IMMEDIATE RELEASE CORE LAB ANNOUNCES Q1 2019 QUARTERLY DIVIDEND AMSTERDAM (15 January 2019) - The Board of Supervisory Directors of Core Laboratories N.
January 15, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): January 15, 2019 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands Not Applicable (State or other jurisd
October 25, 2018	10-Q	CLB / Core Laboratories N.V. 10-Q Q3 2018 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14273 CORE
October 24, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): October 24, 2018 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands Not Applicable (State or other jurisd
October 24, 2018	EX-99.1	CORE LABORATORIES N.V. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (amounts in thousands, except per share data) (Unaudited) Three Months Ended % Variance 9/30/2018 6/30/2018 9/30/2017 vs.Q2-18 vs.Q3-17 REVENUE $ 182,146 $ 175,475 $ 16 FOR IMMEDIATE RELEASE CORE LAB REPORTS THIRD QUARTER 2018 RESULTS FROM CONTINUING OPERATIONS: • REVENUE OF $182.
October 9, 2018	EX-99.1	CORE LAB ANNOUNCES Q4 2018 QUARTERLY DIVIDEND FOR IMMEDIATE RELEASE CORE LAB ANNOUNCES Q4 2018 QUARTERLY DIVIDEND AMSTERDAM (9 October 2018) - The Board of Supervisory Directors of Core Laboratories N.
October 9, 2018	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): October 9, 2018 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands Not Applicable (State or other jurisdi
October 4, 2018	EX-99.1	Wolfe Research Conference Oil Services Panel - Core Laboratories New York - October 4, 2018 Wolfe Research Conference Oil Services Panel - Core Laboratories New York - October 4, 2018 Gwen Schreffler, SVP Corporate Development and Investor Relations and Richard Leonard, Director of Global Technology, Production Enhancement will participate in the Oil Services Panel at the Wolfe Research Utilities and Energy Conference in New York City on Thursday, October 4, 2018.
October 4, 2018	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): October 4, 2018 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands Not Applicable (State or other jurisdi
July 27, 2018	10-Q	CLB / Core Laboratories N.V. 10-Q Q2 2018 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14273 CORE LABOR
July 25, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): July 25, 2018 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands Not Applicable (State or other jurisdict
July 25, 2018	EX-99.1	CORE LABORATORIES N.V. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (amounts in thousands, except per share data) (Unaudited) Three Months Ended % Variance 6/30/18 3/31/18 6/30/17 vs Q1-18 vs Q2-17 REVENUE $ 175,475 $ 170,018 $ 158,212 FOR IMMEDIATE RELEASE CORE LAB REPORTS SECOND QUARTER 2018 RESULTS FROM CONTINUING OPERATIONS: • REVENUE OF $175.
July 13, 2018	EX-99.1	CORE LAB ANNOUNCES Q3 2018 QUARTERLY DIVIDEND FOR IMMEDIATE RELEASE CORE LAB ANNOUNCES Q3 2018 QUARTERLY DIVIDEND AMSTERDAM (13 July 2018) - The Board of Supervisory Directors of Core Laboratories N.
July 13, 2018	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): July 13, 2018 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands Not Applicable (State or other jurisdict
June 29, 2018	EX-99.1	DEFERRED INTERNATIONAL ACTIVITY AFFECTS REVENUE OPPORTUNITIES; CORE LAB UPDATES Q2 2018 GUIDANCE FOR IMMEDIATE RELEASE DEFERRED INTERNATIONAL ACTIVITY AFFECTS REVENUE OPPORTUNITIES; CORE LAB UPDATES Q2 2018 GUIDANCE AMSTERDAM (29 June 2018) - Core Laboratories N.
June 29, 2018	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): June 29, 2018 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands Not Applicable (State or other jurisdict
June 28, 2018	8-K/A	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): June 19, 2018 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands Not Applicable (State or other jurisdi
June 27, 2018	11-K	CLB / Core Laboratories N.V. 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) X ANNUAL REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR TRANSITION REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 (NO FEE REQUIRED) For the transition period from to Commission File Number 001-14273 A. Full t
June 25, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): June 19, 2018 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands Not Applicable (State or other jurisdict
June 25, 2018	EX-10.1	Seventh Amended and Restated Credit Agreement, dated as of June 19, 2018, among Core Laboratories, N.V., and Core Laboratories (U.S.) Interests Holdings, Inc., and the lenders party thereto and Bank of America, N.A., as administrative agent CUSIPS: 21867HAC4 21867HAD2 SEVENTH AMENDED AND RESTATED CREDIT AGREEMENT DATED AS OF JUNE 19, 2018 CORE LABORATORIES N.
May 29, 2018	SD	CLB / Core Laboratories N.V. 2017 CONFLICT MINERALS REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands 001-14273 Not Applicable (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) Strawinskyl
May 29, 2018	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): May 24, 2018 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands Not Applicable (State or other jurisdicti
April 27, 2018	10-Q	CLB / Core Laboratories N.V. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14273 CORE LABO
April 26, 2018	8-K/A	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): April 25, 2018 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands Not Applicable (State or other jurisd
April 26, 2018	EX-99.1	CORE LABORATORIES N.V. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (amounts in thousands, except per share data) Three Months Ended % Variance 3/31/18 12/31/17 3/31/17 vs Q4-17 vs Q1-17 REVENUE $ 170,018 $ 170,111 $ 156,609 (0.1)% 8.6% FOR IMMEDIATE RELEASE CORE LAB REPORTS FIRST QUARTER 2018 RESULTS FROM CONTINUING OPERATIONS: • REVENUE OF $170 MILLION, UP MORE THAN 8% YEAR-OVER-YEAR; FLAT SEQUENTIALLY • OPERATING MARGINS OF 19%, UP 400 BPS YEAR-OVER-YEAR • YEAR-OVER-YEAR INCREMENTAL OPERATING MARGINS OF 65%; 68% EX-ITEMS • GAAP EPS OF $0.
April 25, 2018	EX-99.1	CORE LABORATORIES N.V. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (amounts in thousands, except per share data) Three Months Ended % Variance 3/31/18 12/31/17 3/31/17 vs Q4-17 vs Q1-17 REVENUE $ 170,018 $ 170,111 $ 156,609 (0.1)% 8.6% FOR IMMEDIATE RELEASE CORE LAB REPORTS FIRST QUARTER 2018 RESULTS FROM CONTINUING OPERATIONS: • REVENUE OF $170 MILLION, UP MORE THAN 8% YEAR-OVER-YEAR; FLAT SEQUENTIALLY • OPERATING MARGINS OF 19%, UP 400 BPS YEAR-OVER-YEAR • YEAR-OVER-YEAR INCREMENTAL OPERATING MARGINS OF 65%; 68% EX-ITEMS • GAAP EPS OF $0.
April 25, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): April 25, 2018 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands Not Applicable (State or other jurisdic
April 17, 2018	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): April 17, 2018 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands Not Applicable (State or other jurisdic
April 17, 2018	EX-99	CORE LAB ANNOUNCES Q2 2018 QUARTERLY DIVIDEND FOR IMMEDIATE RELEASE CORE LAB ANNOUNCES Q2 2018 QUARTERLY DIVIDEND AMSTERDAM (17 April 2018) - The Board of Supervisory Directors of Core Laboratories N.
March 23, 2018	DEF 14A	CLB / Core Laboratories N.V. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Defin
March 23, 2018	DEFA14A	CLB / Core Laboratories N.V. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
March 12, 2018	PRE 14A	CLB / Core Laboratories N.V. PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: þ Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
February 14, 2018	SC 13G/A	CLB / Core Laboratories N.V. / WCM INVESTMENT MANAGEMENT/CA - SC 13G/A Passive Investment WCM Investment Management: Form SC 13G/A- Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Core Laboratories NV (Name of Issuer) Common (Title of Class of Securities) N22717107 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the a
February 14, 2018	SC 13G/A	CLB / Core Laboratories N.V. / Clearbridge Investments, LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 12)* CORE LABORATORIES N V (Name of Issuer) Common Stock (Title of Class of Securities) N22717107 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t
February 12, 2018	10-K	CLB / Core Laboratories N.V. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) Q ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14273 CORE LABORATORI
February 12, 2018	EX-3.1	Articles of Association of Core Lab N.V., as amended on May 18, 2017 (including English translation)(incorporated by reference to Exhibit 3.1 to Core Lab N.V.’s form 10-K, filed on February 12, 2018) CONTINUOUS TEXT of the articles of association of Core Laboratories N.V., with corporate seat in Amsterdam, after partial amendment to the articles of association, by deed executed before a deputy of W.H. Bossenbroek, civil law notary in Amsterdam, on 24 May 2017. Trade register number: 33261158. This is a translation into English of the original Dutch text. An attempt has been made to be as liter
February 8, 2018	SC 13G/A	CLB / Core Laboratories N.V. / VANGUARD GROUP INC Passive Investment corelaboratoriesnv.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5 )* Name of issuer: Core Laboratories NV Title of Class of Securities: Common Stock CUSIP Number: N22717107 Date of Event Which Requires Filing of this Statement: December 31, 2017 Check the appropriate
January 31, 2018	EX-99.1	CORE LABORATORIES N.V. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (amounts in thousands, except per share data) Three Months Ended % Variance 31 Dec 2017 30 Sep 2017 31 Dec 2016 vs Q3-17 vs Q4-16 REVENUE $ 171,852 $ 166,247 $ 149,542 Exhibit FOR IMMEDIATE RELEASE CORE LAB REPORTS FOURTH QUARTER 2017 RESULTS: ? REVENUE OF $172 MILLION, UP 15% YEAR-OVER-YEAR AND 3% SEQUENTIALLY ? COMPANY OPERATING INCOME UP 50%YEAR-OVER-YEAR AND UP 18% SEQUENTIALLY ? COMPANY OPERATING MARGINS OF 19%, UP 400 BPS YEAR-OVER-YEAR AND UP 200 BPS SEQUENTIALLY ? GAAP EPS OF $0.
January 31, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): January 31, 2018 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands Not Applicable (State or oth
January 16, 2018	8-K	Regulation FD Disclosure, Financial Statements and Exhibits Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): January 16, 2018 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands Not Applicable (State or oth
January 16, 2018	EX-99.1	CORE LAB ANNOUNCES Q1 2018 QUARTERLY DIVIDEND Exhibit FOR IMMEDIATE RELEASE CORE LAB ANNOUNCES Q1 2018 QUARTERLY DIVIDEND AMSTERDAM (16 January 2018) - The Board of Supervisory Directors of Core Laboratories N.
October 25, 2017	EX-3.1	Articles of Association of Core Laboratories N.V., as amended in 2012 (including English translation) EX-3.1 2 exhibit31-201210xkxarticle.htm EXHIBIT 3.1 CONTINUOUS TEXT of the articles of association of Core Laboratories N.V., with corporate seat in Amsterdam, after partial amendment to the articles of association dated 16 May 2012 before M.D.P. Anker, civil law notary in Amsterdam. Trade register number: 33261158 This is a translation into English of the original Dutch text. An attempt has been
October 25, 2017	10-Q	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14273 CORE
October 23, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): October 23, 2017 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands Not Applicable (State or oth
October 23, 2017	EX-99.1	CORE LABORATORIES N.V. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (amounts in thousands, except per share data) Three Months Ended % Variance 30 Sep 2017 30 Jun 2017 30 Sep 2016 vs Q2-17 vs Q3-16 REVENUE $ 166,247 $ 163,903 $ 143,483 Exhibit FOR IMMEDIATE RELEASE CORE LAB REPORTS THIRD QUARTER 2017 RESULTS: ? REVENUE OF $166 MILLION, UP FROM 2Q 2017 ? GAAP EPS OF $0.
October 10, 2017	8-K	Core Laboratories 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): October 10, 2017 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands Not Applicable (State or oth
October 10, 2017	EX-99.1	CORE LAB ANNOUNCES Q4 2017 QUARTERLY DIVIDEND Exhibit FOR IMMEDIATE RELEASE CORE LAB ANNOUNCES Q4 2017 QUARTERLY DIVIDEND AMSTERDAM (10 October 2017) - The Board of Supervisory Directors of Core Laboratories N.
September 5, 2017	EX-99.1	CORE LAB REPORTS ON IMPACT OF HURRICANE HARVEY, UPDATES THIRD QUARTER 2017 GUIDANCE Exhibit FOR IMMEDIATE RELEASE CORE LAB REPORTS ON IMPACT OF HURRICANE HARVEY, UPDATES THIRD QUARTER 2017 GUIDANCE AMSTERDAM (5 September 2017) - Core Laboratories N.
September 5, 2017	8-K	Core Laboratories 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): September 5, 2017 CORE LABORATORIES N.V. (Exact name of registrant as specified in its charter) 001-14273 (Commission File Number) The Netherlands Not Applicable (State or ot
August 31, 2017	SC 13G/A	CLB / Core Laboratories N.V. / WCM INVESTMENT MANAGEMENT/CA - FORM SC 13G/A Passive Investment WCM Investment Management - Schedule 13G/A - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* CORE LABORATORIES NV (Name of Issuer) Common (Title of Class of Securities) N22717107 (CUSIP Number) July 31, 2017 (Date of Event which Requires Filing of this Statement) Check the ap
July 26, 2017	10-Q	10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14273 CORE LABORATOR
July 26, 2017	10-Q	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14273 CORE LABOR
July 24, 2017	EX-99.1	CORE LABORATORIES N.V. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (amounts in thousands, except per share data) Three Months Ended % Variance 30 Jun 2017 31 Mar 2017 30 Jun 2016 vs Q1-17 vs Q2-16 REVENUE $ 163,903 $ 157,807 $ 148,069 Exhibit FOR IMMEDIATE RELEASE CORE LAB REPORTS SECOND QUARTER 2017 RESULTS: ? REVENUE OF $164 MILLION, UP 4% SEQUENTIALLY FROM 1Q 2017 ? GAAP EPS OF $0.

CLB / Core Laboratories Inc. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

الإحصائيات الأساسية

SEC Filings

SEC Filings (Chronological Order)

Other Listings